Investors have been waiting years for Gilead Sciences to finally recover from its blowup in 2016. That could finally happen in 2024, Jacob Sonenhine writes in this week’s edition of Barron’s. Keeping the same multiple in place and including the dividend, the stock could post an almost double-digit total return by the end of the coming new year. If things go right, there’s lots of additional upside ahead, the author says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD:
- Biotech Alert: Searches spiking for these stocks today
- FDA approves label update for Gilead’s Kite for Yescarta to include OS analysis
- Hookipa Pharma announces $21.25M equity investment from Gilead
- Compugen spikes after deal with Gilead for anti-tumor drug
- Compugen spikes 180% on $848M deal with Gilead for anti-tumor drug
